SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending due to speculation around a potential ETF approval and general excitement for altcoin season, with the community actively discussing institutional investment and real-world use cases. Some investors believe the token is undervalued, while others caution against over-optimism given past performance, dilution and the need for regulatory clarity. Despite differing opinions, there's a consensus that HBAR is showing strength, and an ETF could open the door to institutional investments.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid ongoing speculation of a potential acquisition, with community members highlighting its promising oncology assets and Roche's potential interest. Discussions revolve around Roche's existing collaboration with Tempest and the strategic value of acquiring TPST's liver cancer therapy. Some traders express concerns about cash runway and timing, while others point to technical indicators and potential buyout scenarios, anticipating news soon.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its acquisition of Arduino, a move seen as expanding its reach in AI and robotics. The community is discussing the potential benefits of this acquisition and how it may position the company against competitors. Some traders are closely watching technical indicators and option flow for potential upside.

Perimeter Solutions, Inc. engages in the provision of global solutions for fire safety and specialty products industries. It operates through the Fire Safety and Specialty Products segments. The Fire Safety segment specializes in the formulation, manufacture, and sale of fire retardants and firefighting foams that assist in combating various types of fires, including wildland, structural, flammable liquids, and others. It also offers specialized equipment and services, which include airbase retardant storage, mixing, and delivery equipment, mobile retardant bases, retardant ground application units, mobile foam equipment, and others The Specialty Products segment produces and sells phosphorus pentasulfide (P2S5), primarily used in the preparation of lubricant additives, including a family of compounds called zinc dialkyldithiophosphates (ZDDP) that provide critical anti-wear protection to engine components. The company was founded in 2018 and is headquartered in Clayton, MO.

Perimeter Solutions Inc.

Perimeter Solutions SA

Perimeter Solutions ($PRM) is trending due to a recent USDA agreement and positive analyst ratings, with UBS maintaining a Buy rating and raising the price target. The community is discussing the company's strong financials, potential for long-term growth in fire safety products, and a possible monopoly on USDA-quality fire retardant. Some traders are noting bullish sweep call activity and anticipating upcoming earnings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the company's L- and S-band frequencies are now part of the official global 3GPP standard, potentially enabling direct-to-device satellite connectivity on billions of existing phones; the community is discussing the significance of this standardization and its impact on scalability and partnerships with mobile network operators. Bullish sentiment surrounds the implications of this milestone, with some speculating about future partnerships and government contracts, while bears express concerns about dilution and valuation.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as analysts discuss its bullish momentum and potential for further gains, particularly noting the strong buying opportunity around the "Blue Box" area. Community discussions revolve around Elliott Wave analysis, identifying key support levels and potential paths for continued upside. Broader market commentary suggests a positive outlook for European equities, with some analysts pointing to potential outperformance compared to U.S. markets.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bear -2X Shares

Direxion Daily Gold Miners Index Bear 2X Shares

Amidst fluctuating gold prices, DUST is trending as traders discuss potential corrections in the overbought gold and miners sectors. Community members are weighing in on key psychological levels for gold, like $4000, and whether a significant pullback is imminent. Some traders are using DUST as a hedge against long gold positions, while others debate the merits and risks of leveraged inverse ETFs.

BlackRock Institutional Trust Company N.A. - iShares MSCI Japan ETF

iShares MSCI Japan ETF

EWJ is trending amid discussions of potential shifts in Japanese monetary policy and its impact on the yen. Community members are weighing the ETF's potential amid global economic uncertainty, with some noting technical breakout patterns. Broader market factors, such as inflation and central bank decisions in Japan, are also driving interest.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its potential amid mixed sentiment, influenced by a recent analyst downgrade and news of layoffs. Despite concerns about EV demand and cash burn, the community is also focused on the company's long-term prospects, including the upcoming R2 vehicle and its relationship with Amazon. Technical analysis suggests a possible breakout, with some traders eyeing potential upside based on future production and profitability.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as retail traders speculate on a potential recovery following Q2 earnings, with community members actively discussing Medicare Advantage and Optum segments. Anticipation is building for the upcoming earnings call, where investors are keen to hear about cost pressures, margin recovery, and forward guidance. Community members are weighing the potential impact of MLR and guidance for 2026.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of cancer therapy developer Kronos Bio Inc. (<a class="mention" data-mention="$KRON" data-symbol-id="KRON" href="https://stocktwits.com/symbol/KRON" target="_blank">$KRON</a>) surged over 13% to hit their highest level since Nov. 6, with trading volume spiking more than six times the daily average.&nbsp;The jump came after the company announced a drastic workforce reduction of approximately 83% by the end of the year.&nbsp;The company said this move is part of a broader strategy to implement cost-cutting measures while exploring potential business combinations and/or divesting its remaining preclinical assets to maximize shareholder value.Also, Kronos Bio revealed a leadership change: Deborah Knobelman will be appointed President and Interim CEO, effective Dec. 3.&nbsp;Knobelman will take over from Norbert Bischofberger, who has been with the company since 2018 and will step down to remain on the Board of Directors and serve as an adviser.<figure class="image"><a href="https://stocktwits.com/symbol/KRON"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_27_at_8_56_24_PM_7fc5adb6e1.png" alt="Screenshot 2024-11-27 at 8.56.24 PM.png" width="1318" height="318"></a><figcaption>KRON sentiment and message volume on Nov 27 as of 10:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits climbed higher within the ‘extremely bullish’ territory, accompanied by a significant increase in message volume.&nbsp;<stembedurl>https://stocktwits.com/youspeaktome/message/594265060</stembedurl>The workforce reduction follows an earlier 21% cut announced in March, with Kronos Bio estimating a $3.7 million charge related to the layoffs.&nbsp;As of March 2024, the company reportedly had 62 full-time employees and one part-time employee.Over a week ago, Piper Sandler had lowered its price target on Kronos Bio from $6 to $1 after the company halted development of its lead candidate, istisociclib, due to some adverse events in ovarian cancer patients.&nbsp;Kronos Bio’s stock has fallen around 31% year-to-date, but the latest developments appears to have rekindled optimism among retail investors.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crvo-stock-surges-on-fda-nod-for-ftd-treatment/cJI0xvNRWB">CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled</a>

Kronos Bio’s stock has fallen around 31% year-to-date, but the latest developments appears to have rekindled optimism.

Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up

The company said this move is part of a broader strategy to implement cost-cutting measures.

Equity

The company said this move is part of a broader strategy to implement cost-cutting measures.


Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...

Piper Sandler Remains a Buy on Kronos Bio (KRON)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Kronos Bio (KRON Research Report), with a price target...

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today...

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq...

Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Declines By 10.7%

Kronos Bio, Inc. (NASDAQ:KRON  Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,430,000 shares, a...

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Kronos Bio Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.88
Prev Close	$0.8671
Open	$0.881
Dividend Yield	0.00%
50-Day Moving Average	$0.7988
Beta	1.17
Avg. Volume	1.15M
PE Ratio	-0.82

52-Week High	$1.46
52-Week Low	$0.65
Market Capitalization	$53.65M
EPS (Annual)	-$1.43
Price to Book	0.67
Revenue Per Employee	$984,800.00
Enterprise Value/EBITDA	N/A

KRON
Kronos Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KRON News

KRONKronos Bio Inc